September 17, 2019 / 11:24 AM / a month ago

BRIEF-CRISPR Therapeutics And Viacyte Present Positive In Vitro Data Towards A Potential Immune-Evasive Cell Replacement Therapy For Diabetes At EASD 2019

Sept 17 (Reuters) - CRISPR Therapeutics AG, ViaCyte, Inc:

* CRISPR THERAPEUTICS AND VIACYTE PRESENT POSITIVE IN VITRO DATA TOWARDS A POTENTIAL IMMUNE-EVASIVE CELL REPLACEMENT THERAPY FOR DIABETES AT EASD 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below